Physicochemical Properties
| Molecular Formula | C25H23F3N4O4S |
| Molecular Weight | 532.534734964371 |
| Exact Mass | 532.139 |
| CAS # | 2377151-10-3 |
| PubChem CID | 139524511 |
| Appearance | White to off-white solid powder |
| LogP | 3.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 37 |
| Complexity | 889 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | S(C1C=CC(=CC=1)NC(NC1C=CC(C(F)(F)F)=CC=1)=O)(N1CCC[C@H]1C(NC1C=CC=CC=1)=O)(=O)=O |
| InChi Key | DKFYGSWCJGXEJY-QFIPXVFZSA-N |
| InChi Code | InChI=1S/C25H23F3N4O4S/c26-25(27,28)17-8-10-19(11-9-17)30-24(34)31-20-12-14-21(15-13-20)37(35,36)32-16-4-7-22(32)23(33)29-18-5-2-1-3-6-18/h1-3,5-6,8-15,22H,4,7,16H2,(H,29,33)(H2,30,31,34)/t22-/m0/s1 |
| Chemical Name | (2S)-N-phenyl-1-[4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenyl]sulfonylpyrrolidine-2-carboxamide |
| Synonyms | ZL-0580; ZL 0580 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | HIV transcription is inhibited with low transcription when 8 μM of virally activated PBMC from HIV-infected patients are used for 2 days [1]. Treatment with ZL0580 (10 μM) increases HIV or baseline transcription through PMA [1]. [1] |
| Cell Assay |
Cell Viability Assay[1] Cell Types: HIV-infected human CD4+ T cells. Tested Concentrations: 0-8μM. Incubation Duration: 2 days. Experimental Results: Suppression of HIV in primary CD4+ T cells. A single treatment (8 μM) resulted in an almost complete loss of productive HIV infection in CD4+ T cells. RT-PCR[1] Cell Types: PBMC from viremic HIV-infected patients. Tested Concentrations: 8μM. Incubation Duration: 2 days. Experimental Results: HIV transcription was inhibited ex vivo in PBMCs from viremic HIV-infected individuals. Cytotoxicity assay [1] Cell Types: J-Lat cells. Tested Concentrations: 0-80 μM. Incubation Duration: 1 day and 3 days. Experimental Results: Concentrations below 40 μM did not cause significant cell death. Treatment of J-Lat cells with ZL0580 (10 μM) also did not result in significant cell death at days 2, 7, and 14 compared to NC in PMA-activated and unstimulated cells. |
| References |
[1]. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129(8):3361-3373. [2]. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1). pii: E84. [3]. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25(1):126-132. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~469.46 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8778 mL | 9.3891 mL | 18.7783 mL | |
| 5 mM | 0.3756 mL | 1.8778 mL | 3.7557 mL | |
| 10 mM | 0.1878 mL | 0.9389 mL | 1.8778 mL |